Fresh off a strategic review that will see the company look to limit the outright purchase of patent portfolios and perhaps sell some of its “non-core” patents, Wi-LAN (TSX:WIN, Nasdaq: WILN) is undervalued, says Cantor Fitzgerald analyst Blair Abernethy.
In a research update to clients this morning, Abernethy maintained his “Buy” rating and (U.S.) $4.50 one-year target on Wi-LAN. The analyst says there are several potential catalysts that could unlock the value in the Ottawa-based company’s stock over the next year, including an aggressive share buyback, large license deals, and the divestiture of its patent portfolio.
Yesterday, Wi-LAN announced it had acquired a portfolio of medical patents that relate to Stent technology, the company’s first foray into medical technology. Also announced was the renewal of its license deal with Archos relating to Wi-Fi technologies. While Abernethy doesn’t see the Archos deal as material he does see value in these types of deals because he says they bring validity to Wi-LAN’s long term objective of doubling its recurring revenue base.
Abernethy says that at 2.4x his fiscal 2015 EV/Sales estimate, Wi-LAN is attractively priced compared to its peers, which trade at 2.5x to 4.5x EV/Sales. At $3.33 per share, he notes, the company is trading at approximately the value of its cash and order backlog, about $140-million and $275-million, respectively.
Shares of Wi-LAN on the Nasdaq closed today down .33% to $3.04.
We Hate Paywalls Too!
At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.